Developing
a new class of drugs
for neurodegenerative diseases

Neuromagen Pharma Ltd. Is a pre-clinical stage pharmaceutical company developing a new class of small innovative molecules for the treatment of neurodegenerative diseases including ALS. Our lead drug candidates, are activators of telomerase reverse transcriptase expression – a key surviving enzyme

Our goal is to develop drugs which will delay the onset, and the progression of neurodegenerative diseases and specifically of ALS and improve and extend patients’ lives

Science

Telomerase is a key enzyme for cell lifespan and survival that prevents telomere shortening and the subsequent cellular senescence that is observed after many rounds of cell division.

In addition to its role in telomer re-elongation which increases the cell lifespan, Telomerase catalytic protein component, Telomerase Reverse Transcriptase (TERT), possesses non-canonical functions that enhances the ability of cells and tissues to cope with various cellular damages including oxidative stress.

The neuroprotective effects of telomerase reverse transcriptase (TERT) in the brain and spinal cord were previously demonstrated by us and by others.

We are developing a family of synthetic small molecules (AGS) which activate TERT transcription. Our compounds demonstrated remarkable therapeutic results in various murine models of neurodegenerative diseases, in a dose and time-dependent manner.

In the hSOD1 Tg
murine models of ALS, treatment with AGS-499 delayed the onset and progression of the disease, increased the survival of motor neurons in the mice spinal cord, and increased survival of the mice

When tested on primary murine hippocampal neurons which were subjected to amyloid beta toxicity, treatment with AGS resulted in increased neuronal survival

In-vitro testing of AGS
effects on human mesenchymal stem cells derived from ALS and MS patients demonstrated increased survival and ameliorated oxidative
stress

In the 5XFAD murine
model of Alzheimer
Disease, AGS treatment reduced amyloid beta
plaque burden and
improved cognitive
behavior

Pipeline

AGS499 is our lead drug candidate, currently in preclinical stage of development. AGS499 demonstrated outstanding efficacy in delaying the onset and the progression of ALS in animal models.

AGS499

ALS

AGS534

Neurodegenerative diseases

Team

Gil Ben-Menachem, PhD, MBA

Founder and Chief Executive Officer

Prof. Esther Priel, DSc

Founder and Chief Scientific Officer

Helena Grinberg-Rashi, PhD, MBA

Senior Clinical and Regulatory Advisor

Daniella Bouhnik, BSc

Director of Operations

Scientific Advisory Board

Gil Ben-Menachem, PhD, MBA

Founder and Chief Executive Officer

Prof. Esther Priel, DSc

Founder and Chief Scientific Officer

Helena Grinberg-Rashi, PhD, MBA

Senior Clinical and Regulatory Advisor

Selected Scientific Publications

Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E.

Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis

EMBO Mol Med. 2012 Apr;4(4):313-29. doi: 10.1002/emmm.201200212. Epub 2012 Feb 20.

Tichon A, Eitan E, Kurkalli BG, Braiman A, Gazit A, Slavin S, Beith-Yannai E, Priel E.

Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals

Curr Mol Med. 2013 Jul;13(6):1010-22. doi: 10.2174/1566524011313060013.

Baruch-Eliyahu N, Rud V, Braiman A, Priel E.

Telomerase increasing compound protects hippocampal neurons from amyloid beta toxicity by enhancing the expression of neurotrophins and plasticity related genes

Sci Rep. 2019 Dec 2;9(1):18118. doi: 10.1038/s41598-019-54741-7.

Neuromagen in the Media

Israeli Drug That Slowed Diseases in Mice to Start Human Trials

Israeli Drug That Slowed Alzheimer’s, Als in Mice Gets Funding to Start Trials

Ben-Gurion University Accelerator Company Secures Significant Funding for New Als Treatment

Prof. Priel’s Interview on i24 News

Contact Us

Address

Beer Sheva High Tech Park, 77 HaEnergya St.
P. O. Box 5316, Beer Sheva, Israel

© 2021 Neuromagen Pharma
Design & Development imarkimage

HaEnergia 77, Beer Sheva

Gil Ben-Menachem, PhD, MBA

Founder and Chief Executive Officer

Gil is a life-sciences executive with more than 25 years of experience in public and private pharmaceutical, biotechnology and venture capital companies. Prior to founding Neuromagen he served in various management and business development positions at Teva (NYSE: TEVA), Dexcel, Kitov (NASDAQ,TLV:PPBT), Paramount Biosciences and NIH Tech Transfer. Gil also served as an examiner of the Israeli Innovation Authority, and as Instructor of graduate-level courses in entrepreneurship and management at the Hebrew University. He received his PhD in microbiology from the Hebrew University (2000), completed his postdoctoral training in immunology at the NIH (2005), and his MBA at the University of Maryland (2004). Gil published more than a dozen manuscripts in peer- reviewed journals including PNAS and Nature Biotechnology and is an inventor of several patents.

Prof. Esther Priel, DSc

Founder and Chief Scientific Officer

Esther is a professor of Molecular Biology and the Head of the Laboratory for Nucleic Acids Topology, at the Faculty of Health Sciences, Ben Gurion University of the Negev. Esther and her research group focus is on the involvement of topoisomerases and telomerase in neurodegenerative diseases, cardiovascular disfunction and diabetes. With more than 40 years of research, Esther and her research group published close to 100 scientific publications, and she is the inventor of more than 80 patents. Esther is considered a world expert in the field of neuroprotection by telomerase. Esther received her M.Sc. in Human Genetics from Tel Aviv University, and her D.Sc. from the Technion Institute of Technology. She received several academic awards among them the Fulbright scholar award as a visiting scientist in the National Institute of Health in the USA.

Helena Grinberg-Rashi, PhD, MBA

Senior Clinical and Regulatory Advisor

Helena is a life-science executive with over 15 years of experience in leading roles at pharmaceuticals and medical devices companies. Helena has an extensive background in drug development, clinical development, and regulation, with a proven track record of leading the product development process from concept to clinical studies worldwide, and successful regulatory submissions in Europe and in the USA. Helena is the founder and CEO of Titania Technologies, a Netherlands-based strategic consultancy firm. She serves as an advisor and mentor for life-sciences and healthcare entrepreneurs and start-up's. Helena earned her Ph.D. in molecular medicine and human genetics from Tel Aviv University and her MBA from the Richman University (IDC) Hertzlia.

Daniella Bouhnik, BSc

Director of Operations

Daniella is a Chemical Engineer and our Director of Operations. Prior to joining Neuromagen Daniella served as an Executive Office Manager at Be’er Sheva based real-estate and law firm, as a manager at Pull & Bear fashion retail chain, and as an instructor of physics and mathematics for undergraduate level students. Daniella completed her B.Sc. in Chemical Engineering at the Ben-Gurion University and is a graduate of Ben-Gurion’s Women Entrepreneurs and Oazis Accelerator Programs.